Associate Professor Christoffer Clemmensen from the University of Copenhagen has developed a new type of weight-loss drug that uses the hormone GLP-1 to deliver neuroplasticity-modulating molecules to specific brain areas, significantly enhancing weight loss in mice. This innovative approach could offer a potent alternative to current treatments with fewer side effects and is now moving towards clinical trials. A revolutionary study published in Nature introduces a new obesity treatment that surpasses the weight loss results of current drugs in mice.
This method involves delivering molecules directly to the brain’s appetite control center, influencing neuroplasticity. A new weight-loss drug utilizes the hormone GLP-1 to target brain areas controlling appetite, potentially reducing side effects and improving effectiveness compared to existing drugs, with human trials pending. “I consider the drugs available on the marked today as the first generation of weight-loss drugs.
Now we have developed a new type of weight-loss drug that affects the plasticity of the brain and appears to be highly effective.” So says Associate Professor and Group Leader Christoffer Clemmensen, from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, who is senior author of the new study, which has been published in the prestigious scientific journal Nature . In the study, Christoffer Clemmensen and colleagues demonstrate a new use of the weight loss ho.
